Olmesartan vs. ramipril in elderly hypertensive patients: Review of data from two published randomized, double-blind studies

Stefano Omboni, Ettore Malacco, Jean Michel Mallion, Paolo Fabrizzi, Massimo Volpe

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Hypertension is a frequent condition among individuals over 65 years of age worldwide and is one of the most important risk factors for cardiovascular (CV) disease. Effective drug treatment of elderly hypertensives is usually associated with a marked reduction in CV morbidity and mortality. Among the different classes of antihypertensive agents, angiotensin receptor blockers (ARBs) and ACE-inhibitors are supposed to provide the best efficacy in lowering blood pressure (BP) and protecting target organ damage while featuring a good tolerability profile. However, up to date, few randomized clinical studies have directly compared the activity and safety of ARBs and ACE-inhibitors in elderly hypertensive patients. Aim of this review of published and unpublished pooled data from two recent randomized, double-blind, controlled trials, is to offer a comprehensive head-to-head comparison of the antihypertensive efficacy of the ARB olmesartan medoxomil vs. the ACE-inhibitor ramipril in a large study population including more than 1,400 hypertensive subjects aged 65-89 years with mild-to-moderate essential hypertension. The efficacy of the two drugs was separately evaluated in subgroups of patients classified according to the presence of metabolic syndrome, reduced renal function, CV risk level, gender, class of age, type of arterial hypertension and previous antihypertensive treatments. Olmesartan showed a greater efficacy than ramipril both in terms of clinic BP reduction and rate normalization. Olmesartan appeared significantly superior to ramipril in providing a more homogeneous and long-lasting 24-h BP control and maintaining an effective antihypertensive action in the last 6-h period from drug intake. In subgroups of patients with additional clinical conditions, olmesartan gave comparable, and in some cases greater, BP responses than those achieved with the ACE-inhibitor. The incidence of adverse events was similar for both drugs. Olmesartan may thus represent an effective alternative to ACE-inhibitors among first-line drug treatments for hypertension in older people.

Original languageEnglish
Pages (from-to)1-19
Number of pages19
JournalHigh Blood Pressure and Cardiovascular Prevention
Volume21
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Ramipril
Double-Blind Method
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Angiotensin Receptor Antagonists
Blood Pressure
Pharmaceutical Preparations
Hypertension
Cardiovascular Diseases
Therapeutics
olmesartan
Morbidity
Kidney
Safety
Mortality
Incidence
Population

Keywords

  • Elderly
  • Essential hypertension
  • Olmesartan
  • Ramipril

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine
  • Medicine(all)

Cite this

Olmesartan vs. ramipril in elderly hypertensive patients : Review of data from two published randomized, double-blind studies. / Omboni, Stefano; Malacco, Ettore; Mallion, Jean Michel; Fabrizzi, Paolo; Volpe, Massimo.

In: High Blood Pressure and Cardiovascular Prevention, Vol. 21, No. 1, 2014, p. 1-19.

Research output: Contribution to journalArticle

@article{d530f53f14dc46e5adc18b1fe21216d7,
title = "Olmesartan vs. ramipril in elderly hypertensive patients: Review of data from two published randomized, double-blind studies",
abstract = "Hypertension is a frequent condition among individuals over 65 years of age worldwide and is one of the most important risk factors for cardiovascular (CV) disease. Effective drug treatment of elderly hypertensives is usually associated with a marked reduction in CV morbidity and mortality. Among the different classes of antihypertensive agents, angiotensin receptor blockers (ARBs) and ACE-inhibitors are supposed to provide the best efficacy in lowering blood pressure (BP) and protecting target organ damage while featuring a good tolerability profile. However, up to date, few randomized clinical studies have directly compared the activity and safety of ARBs and ACE-inhibitors in elderly hypertensive patients. Aim of this review of published and unpublished pooled data from two recent randomized, double-blind, controlled trials, is to offer a comprehensive head-to-head comparison of the antihypertensive efficacy of the ARB olmesartan medoxomil vs. the ACE-inhibitor ramipril in a large study population including more than 1,400 hypertensive subjects aged 65-89 years with mild-to-moderate essential hypertension. The efficacy of the two drugs was separately evaluated in subgroups of patients classified according to the presence of metabolic syndrome, reduced renal function, CV risk level, gender, class of age, type of arterial hypertension and previous antihypertensive treatments. Olmesartan showed a greater efficacy than ramipril both in terms of clinic BP reduction and rate normalization. Olmesartan appeared significantly superior to ramipril in providing a more homogeneous and long-lasting 24-h BP control and maintaining an effective antihypertensive action in the last 6-h period from drug intake. In subgroups of patients with additional clinical conditions, olmesartan gave comparable, and in some cases greater, BP responses than those achieved with the ACE-inhibitor. The incidence of adverse events was similar for both drugs. Olmesartan may thus represent an effective alternative to ACE-inhibitors among first-line drug treatments for hypertension in older people.",
keywords = "Elderly, Essential hypertension, Olmesartan, Ramipril",
author = "Stefano Omboni and Ettore Malacco and Mallion, {Jean Michel} and Paolo Fabrizzi and Massimo Volpe",
year = "2014",
doi = "10.1007/s40292-013-0037-9",
language = "English",
volume = "21",
pages = "1--19",
journal = "High Blood Pressure and Cardiovascular Prevention",
issn = "1120-9879",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Olmesartan vs. ramipril in elderly hypertensive patients

T2 - Review of data from two published randomized, double-blind studies

AU - Omboni, Stefano

AU - Malacco, Ettore

AU - Mallion, Jean Michel

AU - Fabrizzi, Paolo

AU - Volpe, Massimo

PY - 2014

Y1 - 2014

N2 - Hypertension is a frequent condition among individuals over 65 years of age worldwide and is one of the most important risk factors for cardiovascular (CV) disease. Effective drug treatment of elderly hypertensives is usually associated with a marked reduction in CV morbidity and mortality. Among the different classes of antihypertensive agents, angiotensin receptor blockers (ARBs) and ACE-inhibitors are supposed to provide the best efficacy in lowering blood pressure (BP) and protecting target organ damage while featuring a good tolerability profile. However, up to date, few randomized clinical studies have directly compared the activity and safety of ARBs and ACE-inhibitors in elderly hypertensive patients. Aim of this review of published and unpublished pooled data from two recent randomized, double-blind, controlled trials, is to offer a comprehensive head-to-head comparison of the antihypertensive efficacy of the ARB olmesartan medoxomil vs. the ACE-inhibitor ramipril in a large study population including more than 1,400 hypertensive subjects aged 65-89 years with mild-to-moderate essential hypertension. The efficacy of the two drugs was separately evaluated in subgroups of patients classified according to the presence of metabolic syndrome, reduced renal function, CV risk level, gender, class of age, type of arterial hypertension and previous antihypertensive treatments. Olmesartan showed a greater efficacy than ramipril both in terms of clinic BP reduction and rate normalization. Olmesartan appeared significantly superior to ramipril in providing a more homogeneous and long-lasting 24-h BP control and maintaining an effective antihypertensive action in the last 6-h period from drug intake. In subgroups of patients with additional clinical conditions, olmesartan gave comparable, and in some cases greater, BP responses than those achieved with the ACE-inhibitor. The incidence of adverse events was similar for both drugs. Olmesartan may thus represent an effective alternative to ACE-inhibitors among first-line drug treatments for hypertension in older people.

AB - Hypertension is a frequent condition among individuals over 65 years of age worldwide and is one of the most important risk factors for cardiovascular (CV) disease. Effective drug treatment of elderly hypertensives is usually associated with a marked reduction in CV morbidity and mortality. Among the different classes of antihypertensive agents, angiotensin receptor blockers (ARBs) and ACE-inhibitors are supposed to provide the best efficacy in lowering blood pressure (BP) and protecting target organ damage while featuring a good tolerability profile. However, up to date, few randomized clinical studies have directly compared the activity and safety of ARBs and ACE-inhibitors in elderly hypertensive patients. Aim of this review of published and unpublished pooled data from two recent randomized, double-blind, controlled trials, is to offer a comprehensive head-to-head comparison of the antihypertensive efficacy of the ARB olmesartan medoxomil vs. the ACE-inhibitor ramipril in a large study population including more than 1,400 hypertensive subjects aged 65-89 years with mild-to-moderate essential hypertension. The efficacy of the two drugs was separately evaluated in subgroups of patients classified according to the presence of metabolic syndrome, reduced renal function, CV risk level, gender, class of age, type of arterial hypertension and previous antihypertensive treatments. Olmesartan showed a greater efficacy than ramipril both in terms of clinic BP reduction and rate normalization. Olmesartan appeared significantly superior to ramipril in providing a more homogeneous and long-lasting 24-h BP control and maintaining an effective antihypertensive action in the last 6-h period from drug intake. In subgroups of patients with additional clinical conditions, olmesartan gave comparable, and in some cases greater, BP responses than those achieved with the ACE-inhibitor. The incidence of adverse events was similar for both drugs. Olmesartan may thus represent an effective alternative to ACE-inhibitors among first-line drug treatments for hypertension in older people.

KW - Elderly

KW - Essential hypertension

KW - Olmesartan

KW - Ramipril

UR - http://www.scopus.com/inward/record.url?scp=84898794645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898794645&partnerID=8YFLogxK

U2 - 10.1007/s40292-013-0037-9

DO - 10.1007/s40292-013-0037-9

M3 - Article

C2 - 24435506

AN - SCOPUS:84898794645

VL - 21

SP - 1

EP - 19

JO - High Blood Pressure and Cardiovascular Prevention

JF - High Blood Pressure and Cardiovascular Prevention

SN - 1120-9879

IS - 1

ER -